Acumen’s cash falls as November Alzheimer’s trial results approach
Acumen ($ABOS) reported $78.6 million of cash, equivalents and marketable securities at the end of its third quarter of 2026, down from $110.2 million three months earlier. Management expects those resources to fund current clinical and operating activities into early 2027. The quarterly operating loss narrowed to $25.8 million from $26.5 million a year earlier as research and development spending declined. The company also specified November for topline results from ALTITUDE-AD, its 542-partici
0